Investigation of DHA Intake in Pregnant and Lactating Women in China
NCT ID: NCT02104544
Last Updated: 2014-12-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1254 participants
OBSERVATIONAL
2014-04-30
2014-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Subjects meeting inclusion criteria and non of the exclusion criteria will be informed of relevant information of the study. Subjects should be voluntarily consent to participate in the study and sign the informed consent form.
Screening of the study is scheduled for as long as 5 months. In this study, additional examinations or other interventions are not required.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Healthy women presenting at their week 17±2 and week 39±2 obstetric examination;
* 18-40 years of age;
* Monocyesis;
* Having signed the informed consent form voluntarity before participating in the study.
LACTATING WOMEN:
* Healthy women presenting at their day 42±7 post-natal visit;
* 18-40 years of age;
* Monocyesis;
* Having signed the informed consent form voluntarily before participating in the study
Exclusion Criteria
* Still experiencing severe vomiting after 16 weeks of pregnancy;
* Women who have heart, liver, kidney, (ALT and AST≥ 1.5 times of normal upper limit, Cr\>normal upper limit) or severe lung disease or laboratory abnormality (i.e.lipid metabolism disorder) that may interfere with the interpretation of study results, as indicated in previous examinations;
* Pregnant woman currently participating in other clinical trials or who have participated in another clinical trial in the last 30 days;
* Women who in the judgement of the investigator cannot be expected to comply with the protocol or study procedures.
18 Years
40 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Peking University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Liu Jianmeng
The Institute of Reproductive and Child Health
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jianmeng Liu, Doctor
Role: STUDY_CHAIR
Peking University
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
14.10.CN.INF
Identifier Type: -
Identifier Source: org_study_id